表紙
市場調査レポート

A型肝炎:パイプライン製品の分析

Hepatitis A - Pipeline Review, H1 2016

発行 Global Markets Direct 商品コード 219723
出版日 ページ情報 英文 32 Pages
即納可能
価格
本日の銀行送金レート: 1USD=105.42円で換算しております。
Back to Top
A型肝炎:パイプライン製品の分析 Hepatitis A - Pipeline Review, H1 2016
出版日: 2016年04月30日 ページ情報: 英文 32 Pages
概要

A型肝炎とは、A型肝炎ウイルスへの感染で発症する肝臓の炎症(刺激・腫れ)のことです。主な症状として、倦怠感や吐き気・嘔吐、肝臓の炎症、食欲不振、暗色尿、筋肉痛、黄疸などが挙げられます。主な疾病素質には、免疫系の弱体化や、違法薬物の使用(注射剤・非注射剤とも)などが含まれています。主な治療法としては、鎮吐剤や鎮痛剤などがあります。

当レポートでは、世界各国でのA型肝炎治療用のパイプライン製品の開発状況について分析し、パイプライン製品の最新動向や、治験の各段階にある製品の一覧、主要企業のプロファイル、主な薬剤の概要、最新の業界動向などを調査しています。

イントロダクション

  • 調査範囲

A型肝炎の概要

治療薬の開発

  • パイプライン製品の概要
  • パイプライン製品の比較分析

A型肝炎:企業で開発中の治療薬

A型肝炎:大学/機関で研究中の治療薬

A型肝炎:パイプライン製品の概況

  • 後期段階の製品
  • 初期段階の製品

A型肝炎:企業で開発中の製品

A型肝炎:大学/機関で研究中の製品

A型肝炎の治療薬開発に従事している企業

  • Beijing Minhai Biotechnology Co., Ltd
  • Sinovac Biotech Ltd.
  • Zydus Cadila Healthcare Limited

A型肝炎:治療薬の評価

  • 単剤製品
  • 併用製品
  • 標的別
  • 分子タイプ別

薬剤プロファイル

A型肝炎:最近のパイプライン動向

A型肝炎:休止中のプロジェクト

付録

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC8067IDB

Summary

Global Markets Direct's, 'Hepatitis A - Pipeline Review, H1 2016', provides an overview of the Hepatitis A pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Hepatitis A, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Hepatitis A and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Hepatitis A
  • The report reviews pipeline therapeutics for Hepatitis A by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Hepatitis A therapeutics and enlists all their major and minor projects
  • The report assesses Hepatitis A therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Hepatitis A

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Hepatitis A
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Hepatitis A pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Hepatitis A Overview
  • Therapeutics Development
    • Pipeline Products for Hepatitis A - Overview
    • Pipeline Products for Hepatitis A - Comparative Analysis
  • Hepatitis A - Therapeutics under Development by Companies
  • Hepatitis A - Therapeutics under Investigation by Universities/Institutes
  • Hepatitis A - Pipeline Products Glance
    • Late Stage Products
    • Early Stage Products
  • Hepatitis A - Products under Development by Companies
  • Hepatitis A - Products under Investigation by Universities/Institutes
  • Hepatitis A - Companies Involved in Therapeutics Development
    • Beijing Minhai Biotechnology Co., Ltd
    • Sinovac Biotech Ltd.
    • Zydus Cadila Healthcare Limited
  • Hepatitis A - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Target
    • Assessment by Molecule Type
  • Drug Profiles
    • (hepatitis A + hepatitis B + hepatitis E) vaccine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • (hepatitis A + hepatitis B) vaccine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • hepatitis A + hepatitis B vaccine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • hepatitis A vaccine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • hepatitis A vaccine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • hepatitis A vaccine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Hepatitis A - Recent Pipeline Updates
  • Hepatitis A - Dormant Projects
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Hepatitis A, H1 2016
  • Number of Products under Development for Hepatitis A - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Products under Development by Companies, H1 2016
  • Products under Investigation by Universities/Institutes, H1 2016
  • Hepatitis A - Pipeline by Beijing Minhai Biotechnology Co., Ltd, H1 2016
  • Hepatitis A - Pipeline by Sinovac Biotech Ltd., H1 2016
  • Hepatitis A - Pipeline by Zydus Cadila Healthcare Limited, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Assessment by Combination Products, H1 2016
  • Number of Products by Stage and Target, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Hepatitis A Therapeutics - Recent Pipeline Updates, H1 2016
  • Hepatitis A - Dormant Projects, H1 2016

List of Figures

  • Number of Products under Development for Hepatitis A, H1 2016
  • Number of Products under Development for Hepatitis A - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Assessment by Combination Products, H1 2016
  • Number of Products by Molecule Types, H1 2016
  • Number of Products by Stage and Molecule Types, H1 2016
Back to Top